Joe is responsible for leading the development strategy and internal R&D efforts for projects within the RTW Foundation portfolio. Prior to joining RTW Foundation, Joe was a staff scientist at Regeneron where he led a team focused on preclinical development of gene therapies and AAV vector engineering. Before Regeneron, Joe was a principal scientist at Pfizer where he developed and led multiple immuno-oncology programs from early-stage discovery up to IND application, working with a diverse array of modalities including lipid/polymeric nanoparticles, PROTACs, ADCs, antibodies, and small molecules. Prior to Pfizer, Joe was a senior scientist at Innovimmune, a biotech startup. During his PhD, Joe developed unique delivery technologies for nucleic acid-based drugs, seeking to modulate immune responses for autoimmune and oncology indications. His PhD work led to two separate first author publications in Molecular Therapy, as well as additional publications throughout his research career.
Joe has a BS in human biology from Michigan State University, a MS in cellular & molecular biology from Eastern Michigan University and a PhD in immunology & biomedical sciences from the Albert Einstein College of Medicine.
Healthcare corporate affairs and advocacy leader skilled in building meaningful alliances between multiple stakeholders including nongovernmental organizations, patient advocates, medical and scientific key opinion leaders, policymakers, and academia. US and global experience across the biopharmaceutical product lifecycle, from early-stage research to commercialization, pricing, access, and distribution. Deep experience in patient engagement, advocacy development, coalition-building, and disease awareness. Strong knowledge and understanding of multiple therapeutic areas including rare disease. Passionate about effecting change for people fighting serious disease, communicating complex science through storytelling, problem solving, and fostering patient-centric cross-functioning teams.
John G. Geisler, Ph.D., Founder & Chief Scientific Officer, Mitochon Pharmaceuticals, Inc. – Expertise in drug discovery in metabolic disease (Pfizer, Ionis, JnJ) with a primary role bringing forward the inception of new ideas. By striving to working at the root of problems and years of attempting to partition lipids to restore insulin sensitivity, Dr. Geisler has built an expertise in mitochondrial energy expenditure. From this work, stemmed a broader understanding of new mitochondrial targeted applications, and significant gaps of pharmacological interventions for insidious movement disorders, neurodegenerative diseases, and trauma. Dr. Geisler holds a Ph.D. in Mammalian Genetics from University of Tennessee, conducted at Oak Ridge National Laboratories (ORNL), and a dual fellowship at Pfizer & Yale University, focused on the physiology of Type-2 diabetes and whole-body flux. Mitochon Pharmaceuticals was launched Nov 2014 along with co-founder, Robert Alonso to understand the merits of mitochondrial uncouplers as a treatment for insidious neurodegenerative diseases by resolving mitochondrial dysfunction common to most, if not all diseases. Our lead compound, MP-101 (2, 4 dinitrophenol), an oral brain penetrant small molecule, completed Phase I in Normal Healthy Volunteers, proving to be safe and well tolerated. Mitochon subsequently started a series of Phase I/IIa 14-day biomarker studies to test the merits of MP-101 to lower damage and increase biogenesis/neurotrophins for repair in sporadic ALS (sALS), Huntington’s, Multiple Sclerosis and Alzheimer’s Disease participants. Recently, the sALS cohort completed with remarkable results and now Mitochon is gearing up for Phase II in the Fall of 2026. Our second molecule, a prodrug, MP-201, is focused on glaucoma and Traumatic Brain Injuries (TBI), including both classic TBI, more common in civilian population and repetitive blast TBI, common among military settings.
Mary joined the Foundation for Sarcoidosis Research as the organization’s first-ever President and Chief Executive Officer in 2020. As President and CEO, Mary serves as the primary representative and spokesperson for FSR and leads the organization’s strategic vision with patient engagement, strategic partnerships, fundraising, advocacy efforts, program direction, and an aggressive communications and research agenda.
Mary brings 35 years of nonprofit leadership and management experience to the role. Prior to joining FSR, she served as Executive Director at The Myositis Association (TMA.) As Executive Director of TMA, McGowan was featured and highlighted as a preeminent rare disease leader by numerous entities including American Autoimmune Related Diseases Association, Global Genes and the National Organization for Rare Diseases for her innovative national campaigns including Women of Color and Myositis and her leading telemedicine initiatives for autoimmune patients during COVID-19.
Prior to her time at TMA, Mary served as CEO of WomenHeart: The National Coalition for Women with Heart Disease. During her 8 years with WomenHeart, McGowan ensured the organization’s long-term growth and sustainability as the leading voice for the 48 million American women living with or at risk of heart disease. McGowan also served as Executive Director of the Allergy & Asthma Network, the leading nonprofit organization dedicated to eliminating suffering and death due to asthma, allergies and related conditions. She held various positions with the American Academy of Pediatrics during her service of 18 years. McGowan earned a Master’s Degree in Human Resources Development from the George Washington University and a B.A. from Trinity University.
Lorenzo Caselotti is a Product Manager – Can & Glass Lines at Sidel S.P.A., based in Parma (Italy), within the Can & Glass Solutions Portfolio Management organisation.
Lorenzo is graduated as an Engineer from the University Politecnico Di Milano, one of Europe’s leading technical universities. With more than 15 years of experience in Sidel Group in different roles related to Project Management (Global Key Account Lead Project Manager, Senior Project Manager) and Business Development for the beer market.
Lorenzo’s background in managing complex packaging-line projects and supporting global beer key accounts helps breweries reduce time-to-market. His experience translating technical requirements into clear commercial offers and smooth project execution supports brewers’ needs understanding to evaluate the most relevant solutions. Having worked closely with international brewers, he understands the operational constraints of high-speed production, quality requirements, sustainable and flexible production, and the need for reliable line ramp-up and after-sales support.
To know more about Lorenzo: https://www.linkedin.com/in/lorenzocaselotti/
Miki Sakata is an RBQM Lead at Daiichi Sankyo, Inc., with a background as a CRA and Study Manager. She has extensive experience leading RBQM initiatives and process development as a Subject Matter Expert, and currently focuses on optimizing quality and efficiency in global clinical development. Based in the U.S. since 2024, she supports the globalization of Japanese pharmaceutical organizations while embracing cultural and environmental differences.
